 VICTORIA, British Columbia ROCKVILLE, Md.--BUSINESS WIRE--Aurinia Pharmaceuticals Inc. NASDAQ: AUPH TSX: AUP the Company announced today that the Companys licensing partner, Otsuka Pharmaceutical Europe Ltd. OPEL, filed an initial Marketing Authorization Application MAA for voclosporin for the treatment of lupus nephritis LN to the European Medicines Agency EMA. LN is a complication of the autoimmune disease systemic lupus erythematosus SLE that seriously impacts the kidney 